Meeder Asset Management’s Insys Therapeutics, Inc. INSY Stock Holding History

Meeder Asset Management’s Portfolio INSY Stock Details INSY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-567	Closed	-$2K	–	1966
2018 Q4	$2K	Buy	567 +230	+68%	+$1.6K	﹤0.01%	1610
2018 Q3	$3K	Buy	337 +59	+21%	+$471	﹤0.01%	1424
2018 Q2	$2.01K	Buy	278 +116	+72%	+$809	﹤0.01%	1415
2018 Q1	$1K	Sell	162 -193	-54%	-$1.59K	﹤0.01%	1524
2017 Q4	$3K	Sell	355 -350	-50%	-$2.29K	﹤0.01%	1465
2017 Q3	$6K	Buy	705 +221	+46%	+$2.28K	﹤0.01%	1242
2017 Q2	$6K	Hold	484	–	–	﹤0.01%	1172
2017 Q1	$5K	Sell	484 -1,513	-76%	-$16.1K	﹤0.01%	1125
2016 Q4	$19K	Buy	+1,997	New	+$22.6K	﹤0.01%	669
2015 Q4	–	Sell	-7	Closed	–	–	879
2015 Q3	$0	Buy	+7	New	+$258	﹤0.01%	736

Other funds holding INSY

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PAM

Panagora Asset Management Boston, Massachusetts $26.7B AUM 36.4% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

RCM

Raging Capital Management Rocky Hill, New Jersey $18.2M AUM 17.75% 1-Year Est. Return

Meeder Asset Management's INSY Position: Q1 2019 in Review

Meeder Asset Management sold out of Insys Therapeutics, Inc. (INSY) in Q1 2019, closing a stake of 567 shares — an estimated $2K sold.

Meeder Asset Management first reported a position in INSY in Q3 2015 and held it in 10 quarters. The position peaked at $19K in Q4 2016. 98 funds tracked by Wall St. Rank hold INSY as of Q1 2019.

Meeder Asset Management reported no remaining Insys Therapeutics, Inc. position as of Q1 2019 after selling out during the quarter.
Meeder Asset Management sold 567 Insys Therapeutics, Inc. shares in Q1 2019, an estimated $2K.
Meeder Asset Management first reported a position in Insys Therapeutics, Inc. in Q3 2015 and held it in 10 quarters.
Meeder Asset Management's Insys Therapeutics, Inc. position peaked at $19K in Q4 2016.
98 funds tracked by Wall St. Rank held Insys Therapeutics, Inc. as of Q1 2019.

Based on Meeder Asset Management's 13F filing for Q1 2019, filed 16 Apr 2019.